Balance Sheet Disclosures

9 Months Ended

Sep. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Disclosures

Note 4 - Balance Sheet Disclosures

Property and equipment consist of the following (in thousands):

	September 30, 2020			December 31, 2019
Lab equipment	$	5,741		$	4,221
Leasehold improvements		1,778			1,894
Computer equipment		871			869
Furniture and fixtures		424			427
Software		633			503
Construction in process		40			592
		9,487			8,506
Less accumulated depreciation		(6,482	)		(6,386	)
Total property and equipment	$	3,005		$	2,120

Depreciation expense for each of the three and nine months ended September 30, 2020 and 2019 was $$0.2 million and 0.6 million, respectively.

Intangible assets consist of the following (in thousands):

	September 30, 2020			December 31, 2019
Patents	$	1,393		$	1,245
Less accumulated amortization		(475	)		(411	)
	$	918		$	834
Purchased technology	$	16,900		$	16,900
Less accumulated amortization		(4,225	)		(2,817	)
	$	12,675		$	14,083
Purchase option		—		$	121
Less accumulated amortization		—			(17	)
	$	—		$	104
Trademarks (indefinite life)	$	74		$	71
Total intangible assets	$	13,667		$	15,092

The Company recorded amortization expense of $0.5 million and $1.6 million for the three and nine months ended September 30, 2020, respectively, and $0.5 million and $1.5 million for the three and nine months ended September 30, 2019, respectively. Amortization related to the remaining net intangible assets is scheduled to amortize as follows (in thousands):

Year Ending December 31,
Remainder of 2020	$	489
2021		1,944
2022		1,938
2023		1,936
2024		1,927
Thereafter		5,359
Total future amortization expense	$	13,593

Accrued liabilities consist of the following (in thousands):

	September 30, 2020		December 31, 2019
Compensation related accruals	$	2,688	$	1,165
Accrued clinical trial expense		699		620
Other expenses		3,566		2,352
Warrant liability, current		—		43
Total accrued liabilities	$	6,953	$	4,180